Literature DB >> 22290968

Low cefepime concentrations during high blood and dialysate flow continuous venovenous hemodialysis.

F Perry Wilson1, Marcus A Bachhuber, Daniel Caroff, Rebecca Adler, Douglas Fish, Jeffrey Berns.   

Abstract

Dosing of cefepime during high blood flow (Qb; 300 ml/min), high dialysate flow (Qd; 3 liter/h) continuous venovenous hemodialysis (CVVHD) is undefined. Six patients on CVVHD had serum and effluent cefepime concentrations measured at 0.5, 1, 2, 6, and 12 h after dosing. Three patients had cefepime concentrations less than the MIC for Pseudomonas aeruginosa. A dose of 2,000 mg every 12 h or 1,000 mg every 8 h may increase time at a therapeutic concentration.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22290968      PMCID： PMC3318326          DOI： 10.1128/AAC.05987-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy.

Authors:  Robin L Trotman; John C Williamson; D Matthew Shoemaker; William L Salzer
Journal:  Clin Infect Dis       Date:  2005-09-12       Impact factor: 9.079

2.  Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration.

Authors:  B Allaouchiche; D Breilh; H Jaumain; B Gaillard; S Renard; M C Saux
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

3.  Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.

Authors:  R S Malone; D N Fish; E Abraham; I Teitelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

4.  Intensity of renal support in critically ill patients with acute kidney injury.

Authors:  Paul M Palevsky; Jane Hongyuan Zhang; Theresa Z O'Connor; Glenn M Chertow; Susan T Crowley; Devasmita Choudhury; Kevin Finkel; John A Kellum; Emil Paganini; Roland M H Schein; Mark W Smith; Kathleen M Swanson; B Taylor Thompson; Anitha Vijayan; Suzanne Watnick; Robert A Star; Peter Peduzzi
Journal:  N Engl J Med       Date:  2008-05-20       Impact factor: 91.245

5.  Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections.

Authors:  Peggy S McKinnon; Joseph A Paladino; Jerome J Schentag
Journal:  Int J Antimicrob Agents       Date:  2008-03-04       Impact factor: 5.283

Review 6.  Intermittent versus continuous renal replacement therapy for acute renal failure in adults.

Authors:  K Rabindranath; J Adams; A M Macleod; N Muirhead
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18

7.  The NxStage System One.

Authors:  William R Clark; Joseph E Turk
Journal:  Semin Dial       Date:  2004 Mar-Apr       Impact factor: 3.455

8.  Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.

Authors:  Lucie Seyler; Frédéric Cotton; Fabio Silvio Taccone; Daniel De Backer; Pascale Macours; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2011-06-06       Impact factor: 9.097
  8 in total
  2 in total

Review 1.  Clinical implications of antibiotic pharmacokinetic principles in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Jeffrey Lipman
Journal:  Intensive Care Med       Date:  2013-09-18       Impact factor: 17.440

2.  Cefepime Pharmacokinetics in Critically Ill Pediatric Patients Receiving Continuous Renal Replacement Therapy.

Authors:  Gideon Stitt; Jennifer Morris; Lindsay Schmees; Joseph Angelo; Ayse Akcan Arikan
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.